ArticleBioinformatics advances2025
ShinyTHOR app: Shiny-built tumor high-throughput omics-based roadmap.
Article in Bioinformatics advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Artificial Intelligence-Guided Prioritization and Experimental Evaluation of Synergistic Target Combinations for Breast Cancer Therapy.Pharmaceuticals (Basel, Switzerland) · 2026Article
- NKGD2 Ligands (NKG2DLs) in Breast Cancer: In Silico Analysis and Narrative Review.International journal of molecular sciences · 2026Review
- Evodiamine Boosts AR Expression to Trigger Senescence and Halt Proliferation in OSCC Cells.Current issues in molecular biology · 2025Article
- Prognostic implications of autophagy and pyroptosis related genes in oral squamous cell carcinoma: research on bioinformatics and experiments.Frontiers in oncology · 2025Article
- Sestrin3 confers resistance to recombinant human arginase in small cell lung cancer by activating Akt/mTOR/ASS1 axis.PloS one · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Motivation: The Cancer Cell Line Encyclopedia (CCLE), launched in 2008, systematically organizes multi-omic and pharmacological data from over 1000 cancer cell lines with molecular dependency maps accessible through the DepMap tool. However, DepMap lacks tools for systematic comparison of mRNAs, miRNAs, proteins, and metabolites, as well as their links to drug responses and gene signatures. Extracting this data externally requires bioinformatics expertise, limiting access for wet-lab researchers. Results: We developed ShinyTHOR, a web app for intuitive access to multi-omic (transcriptomic, metabolomic, methylomic, proteomic, and miRNomic) and drug-related data. It integrates datasets from CCLE, miRTarBase, circInteractome, and the Genomics of Drug Sensitivity in Cancer. ShinyTHOR includes six modules: (1) identifying top/bottom ten cell lines by marker expression or drug IC50, (2) single-sample Gene Set Enrichment Analysis (ssGSEA), (3) multi-analyte expression evaluation, (4) miRNA-target interactions across cancer types, (5) miRNA impact on mRNA translation via protein levels, and (6) circRNA/miRNA modulation. To validate its utility, we applied ShinyTHOR to a gastric cancer prognosis study (GES7). Availability and implementation: ShinyTHOR is freely accessible for non-commercial use at https://alexismurillo.shinyapps.io/ShinyThor, with source code available at https://github.com/Murillo22/ShinyThor.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.